Temozolomide,85622-93-1
- 品牌:absin
- 型号:abs817889
- 产地:中国
- 供应商:爱必信(上海)生物科技有限公司
- 供应商报价:¥632
- 标签:Temozolomide,85622-93-1、Temozolomide,85622-93-1价格、Temozolomide,85622-93-1厂家、替莫唑胺;NSC 362856;CCRG 81045;TZM、Absin、爱必信(上海)生物科技有限公司
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
YZ剂描述: 产品名称:Temozolomide 产品别名:替莫唑胺 英文别名:NSC 362856;CCRG 81045;TZM 靶点:DNA replication CAS:85622-93-1 纯度:>98% 外观:白色至微红色粉末 保存方法:store at -20℃ 描述: Temozolomide is an orally administered alkylating agent used largely in the therapy of malignant brain tumors including glioblastoma and astrocytoma. 溶解性:DMSO : 9.7 mg/mL (50 mM) 体外研究: Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases. Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. 体内研究:After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. 产品信息订购:
产品更多信息请进入爱必信网站咨询 |